Apple will pay Samsung Display USD 250, roughly equivalent to Rp 4,4 juta, for every unit of the newly launched iPhone Duo sold, according to a leak from a Weibo tipster cited by detikINET. The device marks Apple’s entry into the foldable smartphone market, utilizing a book-style foldable design that pairs a 5,4-inch cover screen with a 7,6-inch main internal display, as reported by Kompas.com.
Samsung Secures Three-Year Exclusive Supply Contract for Foldable OLED Panels
According to reports, Apple evaluated multiple component suppliers during the design phase of its first foldable phone. However, LG Display has not yet reached full commercial production for foldable mobile screens, while panels from BOE were rejected by Apple due to quality and reliability concerns that fell short of company standards, as detailed by detikINET. This left Samsung Display as the sole vendor capable of meeting production requirements, resulting in a reported three-year supply contract. AppleInsider noted that Apple was effectively compelled to accept the terms given the lack of viable alternatives in the market.
Manufacturing Complexity and Component Cost Pressures
The cost of the foldable display accounts for a significant portion of the device’s bill of materials. Standard iPhone displays cost Apple roughly USD 70, making the new foldable panel more than three times as expensive and consuming over 10 percent of the retail price per unit. Linda Sui, founder and principal analyst at Smart Analytics Global and former Head of Mobile Device Markets at TechInsights, told The Korea Herald (as reported by Kompas.com) that Samsung Display holds a distinct advantage in manufacturing maturity, production yields, and scale. Samsung’s years of refinement in minimizing screen crease and enhancing panel durability since launching the original Galaxy Fold in 2019 enabled the company to meet Apple’s stringent volume and quality demands.
Did you know? Financial firm Citi estimates that Apple will sell 7,3 million units of the iPhone Duo during its first year on the market, which would direct substantial revenue to Samsung Display based on the reported per-unit screen cost.
Financial Projections and Competitive Tensions
The supply agreement highlights a complex commercial relationship between two fierce smartphone rivals. Even as Samsung Electronics positions its Galaxy Fold series in direct competition with the iPhone Duo, Samsung Display remains deeply embedded in the hardware supply chain for Apple’s flagship products. The device debuted during the introductory presentation led by John Ternus, CEO, who assumed leadership at a time when Apple traditionally relies on dual-vendor competition to drive down component costs. For the foldable lineup over the next three years, however, manufacturing dependency remains concentrated entirely within Samsung’s facilities.
/data/photo/2026/09/11/6aa363dc4e799.jpg "Photo: tekno.kompas.com")
Frequently Asked Questions
How much does Apple pay Samsung for each foldable screen?
According to leaks reported by detikINET, Apple pays Samsung Display USD 250 (approximately Rp 4,4 juta) for each foldable OLED panel used in the iPhone Duo.
Why is Apple exclusively using Samsung displays for the iPhone Duo?
According to industry reporting, LG Display cannot yet manufacture foldable phone displays at scale, and Apple found BOE’s quality and reliability insufficient, leaving Samsung as the only supplier capable of meeting production standards.
How large are the screens on the iPhone Duo?
According to Kompas.com, the device features a 5,4-inch cover screen for closed operation and a 7,6-inch main internal display when opened.
Join the Conversation
What are your thoughts on Apple’s reliance on its biggest competitor for foldable screen technology? Share your views in the comments below or explore our latest tech coverage.
- Food-Stealing Dolphin Bubbles Finds Easy Meal Shortcut
- LG Responds to Smart TV Eavesdropping Controversy
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)